Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

Abstract

Pancreatic cancer is a relatively common tumor of the digestive system， with difficulties in early-stage diagnosis and an extremely high degree of malignancy. Molecular diagnostic technology based on tumor biomarkers， combined with the existing gold standard in clinical practice， is of great clinical significance to achieve early accurate identification， timely treatment and intervention， and reduction in mortality. Previous studies have shown that miRNAs show high specificity in terms of types and expression levels in different pathological stages of pancreatic cancer and can thus be used in monitoring the development and progression of pancreatic cancer. Since a single miRNA has a limited diagnostic potential， the combination of different miRNAs may effectively improve the diagnostic efficiency of early-stage pancreas carcinogenesis. Based on related research advances in recent years， this consensus document aims to fill the gap in molecular diagnostic technology in the guidelines for the clinical diagnosis and treatment of pancreatic cancer and provide expert guidance and recommendations.
- Pancreatic Neoplasms,
- Early Detection of Cancer,
- Biomarkers， Tumor,
- MicroRNAs,
- Expert Consensus

FullText(HTML)

References(20)

References

[1]	ZHENG RS, ZHANG SW, ZENG HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2( 1): 1- 9. DOI: 10.1016/j.jncc.2022.02.002.
[2]	KANDA M, MATTHAEI H, WU J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia[J]. Gastroenterology, 2012, 142( 4): 730- 733. e 9. DOI: 10.1053/j.gastro.2011.12.042.
[3]	MARIN AM, BATISTA M, de AZEVEDO ALK, et al. Screening of exosome-derived proteins and their potential as biomarkers in diagnostic and prognostic for pancreatic cancer[J]. Int J Mol Sci, 2023, 24( 16): 12604. DOI: 10.3390/ijms241612604.
[4]	HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144( 5): 646- 674. DOI: 10.1016/j.cell.2011.02.013.
[5]	HUANG J, GAO G, GE Y, LIU JZ, et al. Development of a serum-based microRNA signature for early detection of pancreatic cancer: a multicenter cohort study[J]. Dig Dis Sci, 2024.[Forthcoming]
[6]	LI H, CHIANG CL, KWAK KJ, et al. Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis[J]. Adv Sci(Weinh), 2024. DOI: 10.1002/advs.202306373.[ Online ahead of Print]
[7]	KAMAL MA, SIDDIQUI I, BELGIOVINE C, et al. Oncogenic KRAS-induced protein signature in the tumor secretome identifies laminin-C2 and pentraxin-3 as useful biomarkers for the early diagnosis of pancreatic cancer[J]. Cancers(Basel), 2022, 14( 11): 2653. DOI: 10.3390/cancers14112653.
[8]	CAVE DD, BUONAIUTO S, SAINZ B Jr, et al. LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer[J]. J Exp Clin Cancer Res, 2022, 41( 1): 315. DOI: 10.1186/s13046-022-02516-w.
[9]	CHEN XB, LIAO XM, ZHENG BL, et al. Differential plasma proteins identified via iTRAQ-based analysis serve as diagnostic markers of pancreatic ductal adenocarcinoma[J]. Dis Markers, 2023, 2023: 5145152. DOI: 10.1155/2023/5145152.
[10]	LUO XL, LIU JJ, WANG HZ, et al. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis[J]. Pharmacol Res, 2020, 156: 104805. DOI: 10.1016/j.phrs.2020.104805.
[11]	ZHAO R, REN S, LI CY, et al. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study[J]. Cancer Med, 2023, 12( 4): 5158- 5171. DOI: 10.1002/cam4.5296.
[12]	CAO YY, ZHAO R, GUO K, et al. Potential metabolite biomarkers for early detection of stage-I pancreatic ductal adenocarcinoma[J]. Front Oncol, 2022, 11: 744667. DOI: 10.3389/fonc.2021.744667.
[13]	SAHNI S, PANDYA AR, HADDEN WJ, et al. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma[J]. Int J Cancer, 2021, 148( 6): 1508- 1518. DOI: 10.1002/ijc.33368.
[14]	SKUBISZ K, DĄBKOWSKI K, SAMBOROWSKA E, et al. Serum metabolite biomarkers for pancreatic tumors: Neuroendocrine and pancreatic ductal adenocarcinomas-a preliminary study[J]. Cancers(Basel), 2023, 15( 12): 3242. DOI: 10.3390/cancers15123242.
[15]	EISSA MAL, LERNER L, ABDELFATAH E, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood[J]. Clin Epigenetics, 2019, 11( 1): 59. DOI: 10.1186/s13148-019-0650-0.
[16]	LI SY, WANG L, ZHAO Q, et al. Genome-wide analysis of cell-free DNA methylation profiling for the early diagnosis of pancreatic cancer[J]. Front Genet, 2020, 11: 596078. DOI: 10.3389/fgene.2020.596078.
[17]	SCHOTT S, YANG RX, STÖCKER S, et al. HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: A case control study[J]. Oncotarget, 2017, 8( 40): 67614- 67625. DOI: 10.18632/oncotarget.18757.
[18]	WU YN, SEUFERT I, AL-SHAHERI FN, et al. DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma[J]. Gut, 2023, 72( 12): 2344- 2353. DOI: 10.1136/gutjnl-2023-330155.
[19]	MAKLER A, ASGHAR W. Exosomal miRNA biomarker panel for pancreatic ductal adenocarcinoma detection in patient plasma: A pilot study[J]. Int J Mol Sci, 2023, 24( 6): 5081. DOI: 10.3390/ijms24065081.
[20]	XIAO D, DONG ZJ, ZHEN LQ, et al. Combined exosomal GPC1, CD82, and serum CA19-9 as multiplex targets: A specific, sensitive, and reproducible detection panel for the diagnosis of pancreatic cancer[J]. Mol Cancer Res, 2020, 18( 2): 300- 310. DOI: 10.1158/1541-7786.MCR-19-0588.

Relative Articles

[1]	Zhiguo LI, Xun MA, Yongan YE, Xianzhao YANG. Regulatory effect of Kangxian Yiai Prescription in a rat model of precancerous lesions of liver cancer： A study based on the mTOR/HIF-1α/VEGF signaling pathway[J]. Journal of Clinical Hepatology, 2024, 40(10): 2049-2054. doi: 10.12449/JCH241019
[2]	Liao WeiRong, Gu Chao, Zhang DaWei. Clinical efficacy of sorafenib in treatment of primary hepatic carcinoma and its effects on serum VEGFR-2 and PLGF levels[J]. Journal of Clinical Hepatology, 2018, 34(6): 1220-1224. doi: 10.3969/j.issn.1001-5256.2018.06.018
[3]	Sun YiFeng, Zhang ChaoXian, Qin YongMei. The Serum Levels of VEGF and TGF-β1 in Patients with Primary Hepatic Carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(2): 205-207.
[4]	Chen Wei, Lu ZhongHua, Deng Jun, Yang XiaoJuan, Huang LiHua. The change in serum TNF-α and sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent[J]. Journal of Clinical Hepatology, 2010, 26(1): 52-54.
[5]	Liu ChengYi, Chen YanDong. Measurement of serum leptin level in acute pancreatitis patients[J]. Journal of Clinical Hepatology, 2009, 25(6): 437-439.
[6]	Lu ZhongHua, Deng Jun, Yang XiaoJuan, Pei Hao, Zhuang LinNi, Chen Wei. TNF α and TGF β1 in the serum of patients with primary hepatic cancer before and after transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2009, 25(6): 435-436.
[7]	Wang Chong, Jiang YanFang, Jin QingLong, Bao WanGuo, Wang Feng, Niu JunQi. The detection of cytokines IFN-γ、TNF-α、IL-4、IL-10 in the serum of patients of liver disease[J]. Journal of Clinical Hepatology, 2009, 25(2): 99-101.
[8]	He YongWen. The effect of TNF-α on express of MMPs and IL-8 of cultured hepatic stellate cell in human liver.[J]. Journal of Clinical Hepatology, 2006, 22(3): 171-173.
[9]	Gao JiJun, Zhang ChenGuang, Yang QingYang. Study of correlation between serum EGF and AFP in primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2005, 21(1): 40-41.
[10]	Wan Wei, Zhang WeiLi, Zhao Juan. Influence to serum endotoxin and TNF-α in cirrhosis patients with beifeida therapy[J]. Journal of Clinical Hepatology, 2005, 21(2): 93-94.
[11]	You Zhen, Zhang XueChun. The relationship of TNF-α、IL-6 in portal vein and hepatic damage in SAP rats[J]. Journal of Clinical Hepatology, 2004, 20(5): 295-296.
[13]	Chen NaiLing, Deng Tao, Bai Ling, Zhang Chang, Chen PeiLan, Li Lin, Chen Hao. The expression of apoptosis by TNF-α, TNFR and Bcl-2 family in chronic liver disease[J]. Journal of Clinical Hepatology, 2002, 18(6): 342-343.
[14]	Chen ZiPing, Liu Qian, Wang WenQi, Yan MingXian. Clinical Study of Serum IL-1β、TNF-α on Bone Metabolism in Patients with Posthepatitic Cirrhosis[J]. Journal of Clinical Hepatology, 2000, 16(4): 216-218.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (1094) PDF downloads(466)

Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

DOI: 10.12449/JCH240306

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expert consensus on the molecular diagnosis of early-stage pancreatic cancer （2023 edition）

DOI: 10.12449/JCH240306

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content